Tvardi Therapeutics

Tvardi is a clinical-stage, biopharmaceutical company focused on novel, oral therapies targeting STAT3 to treat fibrosis-driven diseases with unmet need.

[Tvardi Therapeutics @tvarditherap]

We are looking forward to participating in the upcoming Jefferies Global Healthcare Conference and the Raymond James BioPharma CEO Strategy Series, including fireside chats with Faisal Khurshid and Ryan Deschner, PhD.

Learn more: https://t.co/QGJSMjJM0U

[Tvardi Therapeutics @tvarditherap]

We continue to make significant progress advancing both programs, providing line of sight to two near-term value inflection points:

• June 2026: TTI-109 Phase 1 healthy volunteer topline data and clinical development strategy

• 2H 2026: TTI-101 Phase 1b/2 HCC topline data

[Tvardi Therapeutics @tvarditherap]

Tvardi Therapeutics will host one-on-one investor meetings at the Raymond James Biotech Innovation Symposium in New York City on April 14, 2026. Looking forward to connecting.

[Tvardi Therapeutics @tvarditherap]

Tvardi Therapeutics announces fourth quarter and full-year 2025 results with key clinical milestones in 2026 for both TTI-109 and TTI-101.

[Tvardi Therapeutics @tvarditherap]

Tvardi is looking forward to participating in upcoming investor conferences.
We’ll be engaging with the investment community at events hosted by @JonesTrading, @Oppenheimer & Co., @TD Cowen, and @Barclays.

Learn more: https://t.co/MtA0UTMMZT

[Tvardi Therapeutics @tvarditherap]

Tvardi Therapeutics will present at the 44th Annual #JPM2026 Healthcare Conference, highlighting new Phase 2 REVERT IPF data

Read the full press release: https://t.co/Q8TX6hVq8m

[Tvardi Therapeutics @tvarditherap]

Today, Tvardi Therapeutics announces further Phase 2 REVERT-IPF data, expanding clinical insights.

Read Press Release Here: https://t.co/TIkLKxUJAK
#TvardiTherapeutics

[Tvardi Therapeutics @tvarditherap]

Today, Tvardi Therapeutics reported its third quarter results and provided a corporate update.
🔗 Read the full press release here: https://t.co/qIiov4RKj1

[Tvardi Therapeutics @tvarditherap]

Tvardi CEO Imran Alibhai, Ph.D., will present at the Jefferies Global Healthcare Conference in London on Nov. 18, 2025, at 9:30 a.m. GMT.
Management will also host 1x1 investor meetings Nov. 17–19.
🔗Webcast: https://t.co/DSpbTZi7pD
#JefferiesHealthcare #TvardiTherapeutics

[Tvardi Therapeutics @tvarditherap]

Thank you to Cantor Fitzgerald’s Global Healthcare team for hosting Tvardi! We were honored to participate alongside leading innovators, investors, and executives shaping the future of biopharma.

#TvardiTherapeutics #CantorGlobalHealthcare

[Tvardi Therapeutics @tvarditherap]

Tvardi will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 4, 2025 at 2:10 PM EDT and participate in one-on-one investor meetings.
https://t.co/RSQ5zm59Hm

[Tvardi Therapeutics @tvarditherap]

Tvardi Therapeutics will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30, 2025 at 4:40 PM ET and will hold one-on-one investor meetings. https://t.co/VFWBRlKU4E

[Tvardi Therapeutics @tvarditherap]

The REVERT IPF Phase 2 clinical trial is a randomized, double-blind, placebo-controlled clinical trial of TTI-101 in patients suffering from IPF. Key endpoints include safety and lung function (FVC). Topline data is anticipated in 4Q 2025. https://t.co/FcIzn2Ipov

[Tvardi Therapeutics @tvarditherap]

Tvardi’s Management will participate in the Piper Sandler 3rd Annual Virtual Lung Symposium with ATS Takeaways: Tuesday, May 27, 2025, and the Jefferies Global Healthcare Conference: June 3 – 5, 2025, in New York, NY
https://t.co/w2puhXyRGz

[Tvardi Therapeutics @tvarditherap]

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference
https://t.co/mlbHJ80zK0

[Tvardi Therapeutics @tvarditherap]

https://t.co/gT0EufMuqw

[Tvardi Therapeutics @tvarditherap]

Merger creates a Nasdaq-listed, clinical-stage biopharmaceutical company – Tvardi Therapeutics – developing novel treatments targeting STAT3 to treat fibrosis-driven diseases. Tvardi shares to begin trading under the symbol “TVRD” on April 16, 2025 https://t.co/gT0EufMuqw

[Tvardi Therapeutics @tvarditherap]

Tvardi Therapeutics Announces Publication of Results from First-in-Human Study of TTI-101 in Patients with Advanced Solid Tumors in the Journal Clinical Cancer Research
https://t.co/XwwJHm1TgR

[Tvardi Therapeutics @tvarditherap]

Tvardi management will host one-on-one investor meetings at the TD Cowen 45th Annual Health Care Conference on March 3 – 5, 2025, in Boston, MA. Join us for insights into our Phase 2 STAT3 programs in fibrosis-driven diseases. https://t.co/vFMPaK2umW

[Tvardi Therapeutics @tvarditherap]

Today, we announce a proposed reverse merger with Cara to continue developing novel treatments for fibrosis-driven diseases. We look forward to leveraging our combined resources to advance our STAT3 inhibitor platform through Phase 2 studies in IPF and HCC https://t.co/t2xLXE0FBB